Yaqrit is a clinical stage company focused on the development and commercialisation of novel therapeutics for patients with serious liver disease in areas of high unmet medical need. Yaqrit won two European Horizon 2020 grants - €5.9 million in 2015 for Yaq-001, and €6.4 million in 2016 for Yaq-002. Our third program, Yaq-005, is being developed in a new partnership with a special purpose company. For further information on any of these programs please email email@example.com
March 2019 - First patient treated with Yaq-001 in cirrhosis. - For further details click here
July 24 2017 - First patient treated in trial of a novel liver dialysis device, DIALIVE - See the full press release here
April 22 2017 - ALIVER, an EU funded Liver Dialysis Machine project, is unveiled in Amsterdam at ILC 2017 - See the full news alert here
December 1 2016 - Yaqrit wins €6.4 million EU Horizon 2020 grant to develop the Dialive extra-corporeal liver support (liver "dialysis") system.
November 28 2016 - Yaqrit receives second tranche of Series A investment, £1.4 million.
December 17 2015 - Yaqrit receives investment of £2 million to develop a new treatment for liver disease - To view the full press release - click here
September 7 2015 - Yaqrit's scientific founders publish paper showing that Yaq-001 affects causes of liver disease - Read the paper online here
May 20 2015 - Yaqrit's lead founding scientist, Professor Rajiv Jalan, features on BBC's Horizon - Watch a short clip here.
April 14 2015 - Yaqrit Ltd in €5.9 million EU Horizon 2020 grant win to develop new treatment for cirrhosis, alcoholic and non-alcoholic fatty liver disease. - To view the full press release - click here
The University College Business site
American Association for the Study of Liver Diseases
European Association for the Study of the Liver
European Foundation for the Study of Chronic Liver Failure
A registry and database of public and private clinical studies around the world
European Union Horizon 2020 grants